PE20151536A1 - Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina - Google Patents
Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histaminaInfo
- Publication number
- PE20151536A1 PE20151536A1 PE2015001832A PE2015001832A PE20151536A1 PE 20151536 A1 PE20151536 A1 PE 20151536A1 PE 2015001832 A PE2015001832 A PE 2015001832A PE 2015001832 A PE2015001832 A PE 2015001832A PE 20151536 A1 PE20151536 A1 PE 20151536A1
- Authority
- PE
- Peru
- Prior art keywords
- histamine
- modulators
- receptor
- methyl
- benzoimidazole
- Prior art date
Links
- 102000004187 Histamine H4 receptors Human genes 0.000 title abstract 2
- 108090000796 Histamine H4 receptors Proteins 0.000 title abstract 2
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
- C30B29/54—Organic compounds
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
- C30B7/08—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by cooling of the solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Virology (AREA)
- Materials Engineering (AREA)
- Metallurgy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
Abstract
SE REFIERE A i) UN HEMITARTRATO TETRAHIDRATO DE [5-(4,6-DIMETIL-1H-BENZOIMIDAZOL-2-IL)-4-METIL-PIRIMIDIN-2-IL]-[3-(1-METIL-PIPERIDIN-4-IL)-PROPIL]-AMINA DE FORMULA (I) Y SUS POLIMORFOS; Y ii) UN DIFUMARATO METANOLATO DE [5-(4,6-DIMETIL-1H-BENZOIMIDAZOL-2-IL)-4-METIL-PIRIMIDIN-2-IL]-[3-(1-METIL-PIPERIDIN-4-IL)-PROPIL]-AMINA DE FORMULA (II). TAMBIEN SE REFIERE A METODOS DE PURIFICACION PARA LOS MISMOS Y COMPOSICIONES FARMACEUTICAS. DICHOS COMPUESTOS SON MODULADORES DE LA ACTIVIDAD DEL RECEPTOR DE HISTAMINA H4 SIENDO UTILES PARA EL TRATAMIENTO DE ALERGIA, ASMA, ENFERMEDADES AUTOINMUNITARIAS Y PRURITO
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361773706P | 2013-03-06 | 2013-03-06 | |
| US201361776260P | 2013-03-11 | 2013-03-11 | |
| US201361784909P | 2013-03-14 | 2013-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20151536A1 true PE20151536A1 (es) | 2015-10-28 |
Family
ID=51488591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015001832A PE20151536A1 (es) | 2013-03-06 | 2014-03-06 | Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina |
Country Status (38)
| Country | Link |
|---|---|
| US (4) | US8859575B2 (es) |
| EP (2) | EP2964229B1 (es) |
| JP (1) | JP6471103B2 (es) |
| KR (1) | KR102230383B1 (es) |
| CN (1) | CN105025898B (es) |
| AU (1) | AU2014225675B2 (es) |
| BR (1) | BR112015021463A8 (es) |
| CA (1) | CA2903737C (es) |
| CL (1) | CL2015002434A1 (es) |
| CR (1) | CR20150435A (es) |
| CY (1) | CY1122545T1 (es) |
| DK (1) | DK2964229T3 (es) |
| DO (1) | DOP2016000027A (es) |
| EA (1) | EA201591648A1 (es) |
| ES (1) | ES2773543T3 (es) |
| GT (1) | GT201500243A (es) |
| HR (1) | HRP20200253T1 (es) |
| HU (1) | HUE047681T2 (es) |
| IL (1) | IL240247B (es) |
| JO (1) | JO3516B1 (es) |
| LT (1) | LT2964229T (es) |
| MX (1) | MX373874B (es) |
| MY (1) | MY180726A (es) |
| NZ (1) | NZ710640A (es) |
| PE (1) | PE20151536A1 (es) |
| PH (1) | PH12015501731B1 (es) |
| PL (1) | PL2964229T3 (es) |
| PT (1) | PT2964229T (es) |
| RS (1) | RS59909B1 (es) |
| SA (1) | SA515360981B1 (es) |
| SG (1) | SG11201507117XA (es) |
| SI (1) | SI2964229T1 (es) |
| SM (1) | SMT202000084T1 (es) |
| TW (1) | TWI617554B (es) |
| UA (1) | UA118754C2 (es) |
| UY (1) | UY35370A (es) |
| WO (1) | WO2014138368A1 (es) |
| ZA (1) | ZA201507351B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602007008545D1 (de) | 2006-03-31 | 2010-09-30 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyridine und pyrazine als modulatoren des histamin-h4-rezeptors |
| US9371311B2 (en) | 2008-06-30 | 2016-06-21 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyrimidine derivatives |
| PL2964229T3 (pl) | 2013-03-06 | 2020-05-18 | Janssen Pharmaceutica Nv | Benzoimidazol-2-ilo pirymidynowe modulatory receptora histaminowego H<sub>4</sub> |
| TWI599567B (zh) | 2013-03-14 | 2017-09-21 | 健生藥品公司 | Ｐ２ｘ７調節劑 |
| WO2014152589A1 (en) | 2013-03-14 | 2014-09-25 | Janssen Pharmaceutica Nv | P2x7 modulators |
| WO2014152537A1 (en) | 2013-03-14 | 2014-09-25 | Janssen Pharmaceutica Nv | P2x7 modulators |
| JO3509B1 (ar) | 2013-03-14 | 2020-07-05 | Janssen Pharmaceutica Nv | معدلات p2x7 |
| JP6592510B2 (ja) | 2014-09-12 | 2019-10-16 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｐ２ｘ７調節因子 |
| EP3191488B1 (en) | 2014-09-12 | 2019-08-14 | Janssen Pharmaceutica NV | P2x7 modulating n-acyl-triazolopyrazines |
| CN109963570A (zh) | 2017-01-21 | 2019-07-02 | 宁波知明生物科技有限公司 | 芍药苷-6’-o-苯磺酸酯在治疗干燥综合征的应用 |
| WO2020065614A1 (en) | 2018-09-28 | 2020-04-02 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
| CR20210153A (es) | 2018-09-28 | 2021-05-11 | Janssen Pharmaceutica Nv | Moduladores de monoacilglicerol lipasa |
| CA3156100A1 (en) | 2019-09-30 | 2021-04-08 | Janssen Pharmaceutica Nv | Radiolabelled mgl pet ligands |
| US11891387B2 (en) | 2020-03-26 | 2024-02-06 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3005852A (en) | 1959-12-22 | 1961-10-24 | Gen Aniline & Film Corp | Production of sulfoxides and sulfones |
| GB1062357A (en) | 1965-03-23 | 1967-03-22 | Pfizer & Co C | Quinazolone derivatives |
| US3931195A (en) | 1971-03-03 | 1976-01-06 | Mead Johnson & Company | Substituted piperidines |
| US4191828A (en) | 1976-04-14 | 1980-03-04 | Richardson-Merrell Inc. | Process for preparing 2-(2,2-dicyclohexylethyl)piperidine |
| US4337341A (en) | 1976-11-02 | 1982-06-29 | Eli Lilly And Company | 4a-Aryl-octahydro-1H-2-pyrindines |
| US4190601A (en) | 1978-05-31 | 1980-02-26 | Union Carbide Corporation | Production of tertiary amines by reductive alkylation |
| JPS6130576A (ja) | 1984-07-24 | 1986-02-12 | Ube Ind Ltd | ２−アミノ−５−シアノピリミジンの製法 |
| GB9410031D0 (en) | 1994-05-19 | 1994-07-06 | Merck Sharp & Dohme | Therapeutic agents |
| GB9422391D0 (en) | 1994-11-05 | 1995-01-04 | Solvay Interox Ltd | Oxidation of organosulphur compounds |
| AU4467396A (en) | 1994-12-12 | 1996-07-10 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain, inflammation and spasm |
| WO1997036898A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5880140A (en) | 1996-04-03 | 1999-03-09 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
| US5883105A (en) | 1996-04-03 | 1999-03-16 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| WO1997036890A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5939439A (en) | 1996-12-30 | 1999-08-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| AU5495798A (en) | 1997-01-16 | 1998-08-07 | Sekisui Chemical Co., Ltd. | External preparations for percutaneous absorption |
| AU729869B2 (en) | 1997-01-17 | 2001-02-15 | Merck & Co., Inc. | Integrin antagonists |
| US5945422A (en) | 1997-02-05 | 1999-08-31 | Warner-Lambert Company | N-oxides of amino containing pyrido 2,3-D! pyrimidines |
| EP0973396A4 (en) | 1997-04-07 | 2001-02-07 | Merck & Co Inc | METHOD FOR TREATING CANCER |
| GB9801231D0 (en) | 1997-06-05 | 1998-03-18 | Merck & Co Inc | A method of treating cancer |
| WO1999018079A1 (en) | 1997-10-06 | 1999-04-15 | Warner-Lambert Company | Heteroaryl butyric acids and their derivatives as inhibitors of matrix metalloproteinases |
| KR20010041015A (ko) | 1998-02-17 | 2001-05-15 | 윌리엄 제이. 리플린 | 항바이러스성 피리미딘 유도체 |
| WO1999065897A1 (en) | 1998-06-19 | 1999-12-23 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| DE69908546T2 (de) * | 1999-03-25 | 2004-04-29 | Synthon B.V. | Imidazopyridinderivate und Verfahren zu ihrer Herstellung |
| NZ516348A (en) | 1999-06-23 | 2003-06-30 | Aventis Pharma Gmbh | Substituted benzimidazole |
| TWI279402B (en) | 1999-08-20 | 2007-04-21 | Banyu Pharma Co Ltd | Spiro compounds having NPY antagonistic activities and agents containing the same |
| EA200200422A1 (ru) | 1999-09-30 | 2002-10-31 | Ньюроджен Корпорейшн | НЕКОТОРЫЕ АЛКИЛЕНДИАМИНОЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-а]-1,5-ПИРИМИДИНЫ И ПИРАЗОЛО[1,5-а]-1,3,5-ТРИАЗИНЫ |
| CA2363274A1 (en) | 1999-12-27 | 2001-07-05 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs for hepatitis c |
| DE10006453A1 (de) | 2000-02-14 | 2001-08-16 | Bayer Ag | Piperidylcarbonsäuren als Integrinantagonisten |
| NZ522015A (en) * | 2000-04-24 | 2004-08-27 | Teva Pharma | Zolpidem hemitartrate |
| CN1592621A (zh) * | 2000-04-24 | 2005-03-09 | 特瓦制药工业有限公司 | 唑吡坦半酒石酸盐 |
| JP2004501913A (ja) | 2000-06-23 | 2004-01-22 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | ヘテロアリール−フェニル置換Ｘａ因子阻害剤 |
| AU2001289615A1 (en) | 2000-06-28 | 2002-01-08 | Thromb-X N.V. | Pluripotent embryonic stem (es) cell lines, improved methods for their production, and their use for germ line transmission and for the generation of genetically modified animals |
| IL153662A0 (en) | 2000-07-21 | 2003-07-06 | Syngenta Participations Ag | Process for the preparation of 4,6-dimethoxy-2- (methylsulfonyl)-1,3-pyrimidine |
| EP1317433A2 (en) | 2000-09-06 | 2003-06-11 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| US6624180B2 (en) | 2000-11-20 | 2003-09-23 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade |
| WO2002064096A2 (en) | 2001-02-16 | 2002-08-22 | Tularik Inc. | Methods of using pyrimidine-based antiviral agents |
| MXPA03008143A (es) | 2001-03-09 | 2005-08-16 | Johnson & Johnson | Compuestos heterociclicos. |
| AU2002247402A1 (en) | 2001-03-23 | 2002-10-08 | Chugai Seiyaku Kabushiki Kaisha | Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis |
| WO2002078701A1 (en) | 2001-03-30 | 2002-10-10 | Smithkline Beecham Corporation | Use of pyrazolopyridines as therapeutic compounds |
| CA2446380A1 (en) | 2001-05-08 | 2002-11-14 | Yale University | Proteomimetic compounds and methods |
| AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
| EP1441730B1 (en) * | 2001-11-05 | 2006-08-09 | Merck Patent GmbH | Hydrazono-malonitriles |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| EP1472248A1 (en) | 2002-01-17 | 2004-11-03 | Eli Lilly And Company | Modulators of acetylcholine receptors |
| TWI270542B (en) | 2002-02-07 | 2007-01-11 | Sumitomo Chemical Co | Method for preparing sulfone or sulfoxide compound |
| US7314937B2 (en) | 2002-03-21 | 2008-01-01 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses |
| US7498349B2 (en) | 2002-08-02 | 2009-03-03 | Genesoft Pharmaceuticals, Inc. | Biaryl compounds having anti-infective activity |
| US20040127395A1 (en) | 2002-09-06 | 2004-07-01 | Desai Pragnya J. | Use of histamine H4 receptor modulators for the treatment of allergy and asthma |
| AU2003265886A1 (en) | 2002-09-06 | 2004-03-29 | Janssen Pharmaceutica N.V. | (1H-Benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine H4-receptor antagonists for the treatment of inflammatory and allergic disorders |
| US20040132715A1 (en) | 2002-09-06 | 2004-07-08 | Dunford Paul J. | Method to treat allergic rhinitis |
| ES2264534T3 (es) | 2002-09-06 | 2007-01-01 | Janssen Pharmaceutica N.V. | Compuestos de tienopirrolilo y furanopirrolilo y su utilizacion como ligandos del receptor histaminico h4. |
| CA2499497A1 (en) | 2002-09-27 | 2004-04-08 | Merck & Co., Inc. | Substituted pyrimidines |
| TW200501960A (en) | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
| US20040105856A1 (en) | 2002-12-02 | 2004-06-03 | Robin Thurmond | Use of histamine H4 receptor antagonist for the treatment of inflammatory responses |
| BRPI0409986A (pt) | 2003-05-05 | 2006-05-09 | Hoffmann La Roche | derivados de pirimidina fundida com atividade de crf |
| CA2525547C (en) | 2003-05-14 | 2012-07-03 | Torreypines Therapeutics, Inc. | Compounds and uses thereof in modulating amyloid beta |
| SE0302116D0 (sv) * | 2003-07-21 | 2003-07-21 | Astrazeneca Ab | Novel compounds |
| WO2005039485A2 (en) | 2003-08-13 | 2005-05-06 | Chiron Corporation | Gsk-3 inhibitors and uses thereof |
| KR101127201B1 (ko) | 2003-09-22 | 2012-04-12 | 에스*바이오 피티이 리미티드 | 벤즈이미다졸 유도체와 그의 제조방법 및 약학적 적용 |
| KR20060111466A (ko) | 2003-09-30 | 2006-10-27 | 얀센 파마슈티카 엔.브이. | 퀴녹살린 화합물 |
| KR20060097024A (ko) | 2003-09-30 | 2006-09-13 | 얀센 파마슈티카 엔.브이. | 벤조이미다졸 화합물 |
| EP1670739A4 (en) | 2003-10-08 | 2007-08-08 | Bristol Myers Squibb Co | CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS |
| EP1679309A4 (en) | 2003-10-24 | 2007-03-28 | Ono Pharmaceutical Co | ANTISTRESS MEDICAMENT AND ITS MEDICAL USE |
| US8277831B2 (en) | 2004-02-17 | 2012-10-02 | Advanced Technologies And Regenerative Medicine, Llc. | Drug-enhanced adhesion prevention |
| AU2005226729B2 (en) | 2004-03-25 | 2010-01-28 | Janssen Pharmaceutica N.V. | Imidazole compounds |
| AU2005247808B2 (en) | 2004-05-31 | 2011-02-10 | Msd K.K. | Quinazoline derivative |
| US7250427B2 (en) | 2004-06-30 | 2007-07-31 | Janssen Pharmaceutica, N.V. | Aryl-substituted benzimidazole and imidazopyridine ethers |
| CA2577947A1 (en) | 2004-08-31 | 2006-03-09 | Banyu Pharmaceutical Co., Ltd. | Novel substituted imidazole derivative |
| WO2006042102A2 (en) | 2004-10-05 | 2006-04-20 | Neurogen Corporation | Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds |
| US7381732B2 (en) | 2004-10-26 | 2008-06-03 | Bristol-Myers Squibb Company | Pyrazolobenzamides and derivatives as factor Xa inhibitors |
| US7442716B2 (en) | 2004-12-17 | 2008-10-28 | Merck Frosst Canada Ltd. | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors |
| CN101119973B (zh) | 2004-12-17 | 2011-08-03 | 默克弗罗斯特加拿大有限公司 | 作为mPGES-1抑制剂的2-(苯基或者杂环基)-1H-菲并[9,10-d]咪唑类化合物 |
| AU2006226775A1 (en) | 2005-03-24 | 2006-09-28 | Janssen Pharmaceutica, N.V. | Biaryl derived amide modulators of vanilloid VR1 receptor |
| WO2007044085A2 (en) | 2005-05-19 | 2007-04-19 | Xenon Pharmaceuticals Inc. | Heteroaryl compounds and their uses as therapeutic agents |
| US8193206B2 (en) | 2005-06-14 | 2012-06-05 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
| US20060281712A1 (en) | 2005-06-14 | 2006-12-14 | Chi-Feng Yen | Pyrimidine compounds |
| KR101286569B1 (ko) | 2005-07-04 | 2013-07-23 | 하이 포인트 파마슈티칼스, 엘엘씨 | 신규 약제 |
| RU2008114378A (ru) | 2005-09-13 | 2009-10-20 | Палау Фарма, С.А. (Es) | Производные 2-аминопиримидина как модуляторы активности н4-рецептора гистамина |
| AR056560A1 (es) | 2005-10-06 | 2007-10-10 | Astrazeneca Ab | Pirrolopiridinonas como moduladores cb1 |
| JP5301999B2 (ja) | 2005-10-31 | 2013-09-25 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｃｅｔｐ阻害薬 |
| WO2007063935A1 (ja) | 2005-12-02 | 2007-06-07 | Mitsubishi Tanabe Pharma Corporation | 芳香族化合物 |
| JP2009527508A (ja) | 2006-02-24 | 2009-07-30 | メルク フロスト カナダ リミテツド | ２−（フェニル又は複素環）−１ｈ−フェナントロ［９，１０−ｄ］イミダゾール |
| DE602007008545D1 (de) | 2006-03-31 | 2010-09-30 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyridine und pyrazine als modulatoren des histamin-h4-rezeptors |
| DE602007008859D1 (de) | 2006-03-31 | 2010-10-14 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyridine als modulatoren des histamin-h4-rezeptors |
| JP5132673B2 (ja) | 2006-04-07 | 2013-01-30 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒスタミンｈ４受容体のモジュレーターとしてのインドールおよびベンゾイミダゾール |
| EP2010177A2 (en) | 2006-04-10 | 2009-01-07 | Janssen Pharmaceutica N.V. | Combination histamine h1r and h4r antagonist therapy for treating pruritus |
| EP2019675A4 (en) | 2006-05-02 | 2011-03-02 | Merck Frosst Canada Ltd | METHOD FOR THE TREATMENT OR PREVENTION OF NEOPLASIA |
| US20090209571A1 (en) | 2006-05-18 | 2009-08-20 | Bernard Cote | Phenanthrene derivatives as MPGES-1 inhibitors |
| CN101511190A (zh) | 2006-07-11 | 2009-08-19 | 詹森药业有限公司 | 组胺h4受体的苯并呋喃并-和苯并噻吩并嘧啶调节剂 |
| US8779154B2 (en) * | 2006-09-26 | 2014-07-15 | Qinglin Che | Fused ring compounds for inflammation and immune-related uses |
| TW200904437A (en) | 2007-02-14 | 2009-02-01 | Janssen Pharmaceutica Nv | 2-aminopyrimidine modulators of the histamine H4 receptor |
| WO2009068512A1 (en) | 2007-11-30 | 2009-06-04 | Palau Pharma, S. A. | 2 -amino-pyrimidine derivatives as histamine h4 antagonists |
| US8084466B2 (en) | 2007-12-18 | 2011-12-27 | Janssen Pharmaceutica Nv | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor |
| NZ603069A (en) | 2008-06-12 | 2013-08-30 | Janssen Pharmaceutica Nv | Use of histamine h4 antagonist for the treatment of post-operative adhesions |
| US8841287B2 (en) | 2008-06-12 | 2014-09-23 | Janssen Pharmaceutica N.V. | Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor |
| CA2729733C (en) | 2008-06-30 | 2016-10-25 | Janssen Pharmaceutica Nv | Process for the preparation of substituted pyrimidine derivatives |
| EP2303869A2 (en) * | 2008-06-30 | 2011-04-06 | Janssen Pharmaceutica, N.V. | Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives |
| US8852569B2 (en) * | 2008-08-28 | 2014-10-07 | The General Hospital Corporation | Prevention and treatment of itch with cysteine protease inhibition |
| IT1395963B1 (it) * | 2009-06-04 | 2012-11-02 | Rottapharm Spa | Forme cristalline di 6-(1h-imidazol-1-il)-2-fenil chinazolina e dei suoi sali |
| TWI519533B (zh) | 2010-11-01 | 2016-02-01 | Ｌｇ生命科學有限公司 | １－｛（２Ｓ）－２－胺基－４－［２，４－雙（三氟甲基）－５，８－二氫吡啶并［３，４－ｄ］嘧啶－７（６Ｈ）－基］－４－側氧丁基｝－５，５－二氟哌啶－２－酮酒石酸鹽之水合物 |
| EP2465498A1 (en) | 2010-11-23 | 2012-06-20 | Faes Farma, S.A. | Diphenyl-amine derivatives: uses, process of synthesis and pharmaceutical compositions |
| PL2964229T3 (pl) | 2013-03-06 | 2020-05-18 | Janssen Pharmaceutica Nv | Benzoimidazol-2-ilo pirymidynowe modulatory receptora histaminowego H<sub>4</sub> |
-
2014
- 2014-03-06 PL PL14760540T patent/PL2964229T3/pl unknown
- 2014-03-06 MX MX2015011688A patent/MX373874B/es active IP Right Grant
- 2014-03-06 HU HUE14760540A patent/HUE047681T2/hu unknown
- 2014-03-06 SM SM20200084T patent/SMT202000084T1/it unknown
- 2014-03-06 ES ES14760540T patent/ES2773543T3/es active Active
- 2014-03-06 DK DK14760540.6T patent/DK2964229T3/da active
- 2014-03-06 WO PCT/US2014/021130 patent/WO2014138368A1/en not_active Ceased
- 2014-03-06 EP EP14760540.6A patent/EP2964229B1/en active Active
- 2014-03-06 SG SG11201507117XA patent/SG11201507117XA/en unknown
- 2014-03-06 RS RS20200160A patent/RS59909B1/sr unknown
- 2014-03-06 SI SI201431440T patent/SI2964229T1/sl unknown
- 2014-03-06 NZ NZ710640A patent/NZ710640A/en not_active IP Right Cessation
- 2014-03-06 UY UY0001035370A patent/UY35370A/es unknown
- 2014-03-06 TW TW103107723A patent/TWI617554B/zh not_active IP Right Cessation
- 2014-03-06 KR KR1020157026804A patent/KR102230383B1/ko not_active Expired - Fee Related
- 2014-03-06 HR HRP20200253TT patent/HRP20200253T1/hr unknown
- 2014-03-06 AU AU2014225675A patent/AU2014225675B2/en not_active Ceased
- 2014-03-06 CN CN201480012369.2A patent/CN105025898B/zh not_active Expired - Fee Related
- 2014-03-06 MY MYPI2015702907A patent/MY180726A/en unknown
- 2014-03-06 PT PT147605406T patent/PT2964229T/pt unknown
- 2014-03-06 LT LTEP14760540.6T patent/LT2964229T/lt unknown
- 2014-03-06 PE PE2015001832A patent/PE20151536A1/es not_active Application Discontinuation
- 2014-03-06 EA EA201591648A patent/EA201591648A1/ru unknown
- 2014-03-06 JP JP2015561646A patent/JP6471103B2/ja not_active Expired - Fee Related
- 2014-03-06 US US14/199,634 patent/US8859575B2/en active Active
- 2014-03-06 JO JOP/2014/0074A patent/JO3516B1/ar active
- 2014-03-06 BR BR112015021463A patent/BR112015021463A8/pt not_active Application Discontinuation
- 2014-03-06 CA CA2903737A patent/CA2903737C/en active Active
- 2014-03-06 EP EP19213615.8A patent/EP3660011A1/en not_active Withdrawn
- 2014-06-03 UA UAA201509634A patent/UA118754C2/uk unknown
- 2014-08-21 US US14/465,677 patent/US9278952B2/en not_active Expired - Fee Related
-
2015
- 2015-07-30 IL IL240247A patent/IL240247B/en active IP Right Grant
- 2015-08-06 PH PH12015501731A patent/PH12015501731B1/en unknown
- 2015-08-24 CR CR20150435A patent/CR20150435A/es unknown
- 2015-08-31 CL CL2015002434A patent/CL2015002434A1/es unknown
- 2015-09-02 GT GT201500243A patent/GT201500243A/es unknown
- 2015-09-03 SA SA515360981A patent/SA515360981B1/ar unknown
- 2015-10-05 ZA ZA2015/07351A patent/ZA201507351B/en unknown
-
2016
- 2016-01-22 DO DO2016000027A patent/DOP2016000027A/es unknown
- 2016-02-18 US US15/047,359 patent/US9434715B2/en not_active Expired - Fee Related
- 2016-08-03 US US15/227,878 patent/US9663497B2/en not_active Expired - Fee Related
-
2020
- 2020-02-03 CY CY20201100085T patent/CY1122545T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20151536A1 (es) | Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina | |
| MX2016008131A (es) | Compuestos heterociclos biciclicos y sus usos en terapia. | |
| EA201591087A1 (ru) | Новые производные бензимидазола в качестве антагонистов рецептора ep4 | |
| MX374729B (es) | Compuestos de heteroarilo o arilo biciclicos fusionados y su uso como inhibidores irak4. | |
| MX2017004200A (es) | Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos. | |
| CR20150370A (es) | Compuestos antivirales | |
| UY35675A (es) | Derivados sustituidos de quinazolin-4-ona | |
| CU20140048A7 (es) | Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos | |
| CR20210079A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| CO6781507A2 (es) | Novedosos derivados heterociclicos | |
| SV2018005760A (es) | Derivados de aminotiazol utiles como agentes antiviricos | |
| MX387228B (es) | Compuestos de pirazol como moduladores del receptor de hormona estimuladora de foliculo y sus usos. | |
| ECSP17010481A (es) | Novedosas pirimidinas 2,5-sustituidas | |
| CL2016000436A1 (es) | Método para el tratamiento de la enfermedad fibrótica | |
| UY35906A (es) | Novedosos derivados de bencimidazol como ligandos de ep4 | |
| CR20140257A (es) | Nuevos 2h-indazoles como antagonistas del receptor ep2 | |
| EA201790939A1 (ru) | ТРИАЗОЛО[4,5-d]ПИРИМИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ КАННАБИНОИДНЫХ РЕЦЕПТОРОВ ТИПА 2 | |
| DOP2016000312A (es) | Compuestos derivados de 1-(ciclopent-2-en-1-il)-3-(2-hidroxi-3-(arilsulfonil)fenil)urea como inhibidores cxcr2 | |
| ECSP17010482A (es) | Novedosas pirimidinas 2,5-sustituidas | |
| DOP2016000064A (es) | Derivados de fenilalanina sustituidos | |
| ECSP13013016A (es) | Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona, y su uso como inhibidores de la cinasa del receptor vegf | |
| MX373636B (es) | Compuestos de azetidiniloxifenilpirrolidina. | |
| UY35785A (es) | Derivados de piperazina sustituidos como moduladores del transportador de la glicina-1 (glyt1) | |
| MX374323B (es) | Compuestos de heteroarilo y métodos de uso de los mismos. | |
| CL2012003253A1 (es) | Compuestos derivados de 1,3,4-tiadiazol alquilamidas y de chalconas, antagonistas del receptor trpv-1; uso de los compuestos para tratar el dolor cronico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |